Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis.
about
The distribution of new HIV infections by mode of exposure in MoroccoHIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesisComparison of HIV-, HBV-, HCV- and co-infection prevalence between Chinese and Burmese intravenous drug users of the China-Myanmar border regionHigh prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, ChinaBurden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the communityEconomic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal studyPotential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitisChanges in blood-borne infection risk among injection drug users.The geographic distribution patterns of HIV-, HCV- and co-infections among drug users in a national methadone maintenance treatment program in Southwest China.Recent HIV-1 Outbreak Among Intravenous Drug Users in Romania: Evidence for Cocirculation of CRF14_BG and Subtype F1 Strains.Increasing prevalence of HIV infection among first time clients in Italian drug treatment services - is it sexual transmission?Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort CollaborationHepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject drugs in the Middle East and North Africa.HCV prevalence can predict HIV epidemic potential among people who inject drugs: mathematical modeling analysisHCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infectionParallel declines in HIV and hepatitis C virus prevalence, but not in herpes simplex virus type 2 infection: A 10-year, serial cross-sectional study in an inner-city emergency department.HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.Prevalence and Clinical Impact of Human Pegivirus-1 Infection in HIV-1-Infected Individuals in Yunnan, China.Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review.Sexual network drivers of HIV and herpes simplex virus type 2 transmission.Rapid Decline in HIV Incidence Among Persons Who Inject Drugs During a Fast-Track Combination Prevention Program After an HIV Outbreak in Athens.Emerging Risks Due to New Injecting Patterns in Hungary During Austerity Times.The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam.Possible HIV transmission modes among at-risk groups at an early epidemic stage in the Philippines.Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study.Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?The investigation of HIV and HCV infection and risk factors among opiate drug users in Beijing, China.Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.Insights on the Russian HCV Care Cascade: Minimal HCV Treatment for HIV/HCV Co-infected PWID in St. Petersburg.Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence.
P2860
Q26826806-DD970FC8-BCB4-4353-9F7F-AA2679231BDFQ27013667-FC01625F-71EA-4CE1-987E-1AF694C7B296Q28476802-190C9BFC-1969-447D-A595-694809BD9955Q28482312-A58C2776-987D-4497-AC93-822F628F2814Q28488313-1821C143-A9B7-4771-9F82-32D47E35EBEEQ28535029-9A86ABC1-6266-4FE1-8504-70258AA76A21Q34255407-F13902AC-BE81-49D5-A45E-2791D22512A9Q34260671-4484330C-E090-41E7-9097-BA52797600C1Q34772870-930F5624-E1B7-4A84-A9BA-E5D21385CC4DQ35115722-822D188C-7B83-4315-B448-E1134C50581FQ35589809-E966D3C1-E7F4-496B-94F5-7234A48A8462Q35604603-4CE93812-E1D9-4607-828E-5FCAE431BAECQ35864236-B343E396-E524-4818-9126-7E256ED4E5DAQ35875495-471E5037-727B-4410-BCF6-C743545C7AAFQ35970414-8880ED4A-E1D6-4632-BE4F-73E03921E4A7Q36212240-DC946B85-5404-4088-ACAD-6AC7BD24E1ECQ36748931-7DE3BD34-768D-48D7-A1AE-3A1E221C7CA5Q36994022-5ABCB50D-AADD-4062-9D18-9BEFB3225C41Q37043264-04D07655-77D6-45E3-914E-4C1E05555FEAQ37676091-AB8ED784-0198-4E1F-B4F1-AE97F55E19C2Q38255693-D6690CAD-41BF-4F2A-9578-B298A05EF27DQ38780675-32E7F010-F3D5-4647-8122-C552F3584EE8Q38838275-09B7A782-39A0-4B16-8F9D-45D7FCF77EA8Q39028755-C2666DF4-C9CC-46C0-AF87-FCCF0FE4F926Q39707313-A3F57DAA-EC17-49C1-9AFA-607491355BA1Q40131973-7D849EBC-CF39-4D56-8827-3C6E34C12A71Q40286008-80622C41-9727-423E-9BB9-D983DF317AC4Q40364008-A60B4C21-D46F-45B9-BE9C-45358BFA1464Q43047551-ABDBEBAE-630D-4C4F-9BA8-3BE84F895094Q45363548-EF572C4C-6E2E-4331-B610-D562A365AE8FQ52312138-961C768E-9DC1-4CEC-9745-B417568C43FAQ55400647-358DC580-7018-4B4C-9962-513A17FF262F
P2860
Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Can hepatitis C virus prevalen ...... users? An ecological analysis.
@en
Can hepatitis C virus prevalen ...... users? An ecological analysis.
@nl
type
label
Can hepatitis C virus prevalen ...... users? An ecological analysis.
@en
Can hepatitis C virus prevalen ...... users? An ecological analysis.
@nl
prefLabel
Can hepatitis C virus prevalen ...... users? An ecological analysis.
@en
Can hepatitis C virus prevalen ...... users? An ecological analysis.
@nl
P50
P1433
P1476
Can hepatitis C virus prevalen ...... users? An ecological analysis
@en
P2093
Lucas Wiessing
P304
P356
10.1111/J.1360-0443.2009.02759.X
P407
P577
2009-11-16T00:00:00Z